Advertisement
Advertisement

INCY

INCY logo

Incyte Genomics Inc

127.49
USD
Sponsored
-0.51
-0.40%
Sep 04, 11:15 UTC -4
Open

INCY Earnings Reports

Positive Surprise Ratio

INCY beat 22 of 42 last estimates.

52%

Next Report

Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.51B
/
-$3.45
Implied change from Q2 26 (Revenue/ EPS)
-10.09%
/
-211.65%
Implied change from Q3 25 (Revenue/ EPS)
+10.19%
/
-253.33%

Incyte Genomics Inc earnings per share and revenue

On Jul 28, 2026, INCY reported earnings of 3.09 USD per share (EPS) for Q2 26, beating the estimate of 2.14 USD, resulting in a 44.14% surprise. Revenue reached 1.67 billion, compared to an expected 1.50 billion, with a 11.37% difference. The market reacted with a +9.30% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of -3.45 USD, with revenue projected to reach 1.51 billion USD, implying an decrease of -211.65% EPS, and decrease of -10.09% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-
Surprise
-
logo
Anavex Life Sciences
Report Date
Aug 25, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
logo
Molecular Partners AG - ADR
Report Date
Aug 25, 2026 For Q2 26
Estimate
-
Actual
-$0.35
Surprise
-
FAQ
For Q2 2026, Incyte Genomics Inc reported EPS of $3.09, beating estimates by 44.14%, and revenue of $1.67B, 11.37% above expectations.
The stock price moved up 9.3%, changed from $118.87 before the earnings release to $129.93 the day after.
The next earning report is scheduled for Oct 26, 2026.
Based on 12 analysts, Incyte Genomics Inc is expected to report EPS of -$3.45 and revenue of $1.51B for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement